Medial EarlySign Recognized as an IDC Innovator for Applying AI to Patient Engagement in Healthcare

Share:

Share on twitter
Share on linkedin
Share on facebook
Share on email

Medial EarlySign Recognized as an IDC Innovator for Applying AI to Patient Engagement in Healthcare

IDC Innovators report Highlights Innovative New Technologies Utilizing AI to Provide Valuable Insights and Recommendations to Healthcare Organizations

 

TEL AVIV, Israel – June 30, 2020 Medial EarlySign™ (earlysign.com), a leader in AI-based clinical solutions to aid in the early detection and prevention of high-burden diseases, today announced it has been named by leading analyst firm International Data Corporation (IDC) as an IDC Innovator applying AI to patient engagement in healthcare.

The IDC Innovators: AI for Patient Engagement, 2020 (doc #US46298920, June 2020) profiles five companies applying AI to enhance patient engagement, including technology to analyze and identify patients with health risks, improve workflow to manage patients, and communicate effectively with patients.

EarlySign’s proprietary AI solutions (AlgoMarkers™) combine laboratory, clinical, and routine electronic health record data to help healthcare organizations prioritize and facilitate care. The technology flags individuals at high risk of a variety of conditions, indicating which patients would benefit from further evaluation, care, and disease management.

“Inclusion in this report highlights the value that our technology brings to healthcare organizations in helping to achieve their patient care goals,” said Jeremy Orr MD, CEO of Medial EarlySign. “Our rigorous, clinically-validated solutions enhance the quality and experience of care provided to patients and help improve clinical workflow. We are proud to be recognized as an IDC Innovator for advancing AI in patient care.”

# # #

About IDC Innovators

IDC Innovators reports present a set of vendors – under $100M in revenue at time of selection — chosen by an IDC analyst within a specific market that offer an innovative new technology, a groundbreaking approach to an existing issue, and/or an interesting new business model. It is not an exhaustive evaluation of all companies in a segment or a comparative ranking of the companies. Vendors in the process of being acquired by a larger company may be included in the report provided the acquisition is not finalized at the time of publication of the report.  Vendors funded by venture capital firms may also be included in the report even if the venture capital firm has a financial stake in the vendor’s company. IDC INNOVATOR and IDC INNOVATORS are trademarks of International Data Group, Inc.

 

About Medial EarlySign

Medial EarlySign helps healthcare systems with early detection and prevention of high-burden diseases. Their suite of outcome-focused software solutions (AlgoMarkers™) find subtle, early signs of high-risk patient trajectories in existing lab results and ordinary EHR data already collected in the course of routine care. EarlySign’s AlgoMarkers can help clients identify patients at high risk for conditions such as lower GI disorders, prediabetic progression to diabetes, and downstream diabetic complications such as chronic kidney disease (CKD). The algorithmic models developed using the company’s machine learning approach are supported by peer-reviewed research published by internationally recognized health organizations and hospitals. Founded in 2013, Medial EarlySign is headquartered in Tel Aviv, Israel with US headquarters in Colorado. For more information, please visit: https://earlysign.com/.

Follow Medial EarlySign on LinkedIn: Medial EarlySign and Twitter: @MedialEarlySign

Share:

Share on twitter
Share on linkedin
Share on facebook
Share on email

Are you looking to solve high-burden disease challenges?